Drug Safety Bill From Sens. Kennedy And Enzi Faces Rival Version In The House
This article was originally published in The Pink Sheet Daily
Executive Summary
Reps. Waxman and Markey introduce legislation to give FDA stronger post-market enforcement authority, including higher fines than in a Senate version of the bill.
You may also be interested in...
PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language
April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.
PDUFA Bill Moves To Senate Mark-Up, But Without Generic Biologics Language
April 18 session is planned in the HELP Committee as advocates for follow-on pathway continue to press their case.
FDA Doesn’t Need New “Hammers” For Drug Safety, Gottlieb Says
Deputy commissioner says that improving technology, not revamping the agency’s oversight authority, will lead to post-marketing improvements.